890 likes | 1.07k Vues
Congenital and Perinatal Infection. Congenital Infections: Presentation. Intrauterine growth retardation Microcephaly Hydrocephalus Intracranial calcifications Thrombocytopenia Blueberry muffin skin rash Hepatosplenomegaly, conjugated hyperbilirubinemia Chorioretinitis Cataracts.
E N D
Congenital Infections: Presentation • Intrauterine growth retardation • Microcephaly • Hydrocephalus • Intracranial calcifications • Thrombocytopenia • Blueberry muffin skin rash • Hepatosplenomegaly, conjugated hyperbilirubinemia • Chorioretinitis • Cataracts
Etiologies of Congenital Infection • Toxoplasmosis T • Syphilis Other • Rubella R • Cytomegalovirus C • Herpes simplex H • HIV • Lymphocytic choriomeningitis virus • Parvovirus B19 • Varicella
Diagnosis of Congenital Infection:General Tests • CBC • Total/direct bilirubin, liver enzymes • Total IgM • Bone radiographs • CSF exam • Eye exam • CNS imaging
Diagnosis of Congenital Infection:Specific Tests • Toxoplasmosis IgM, IgG • RPR • Rubella IgM • Rubella culture: eye, urine, nasopharynx • Urine culture for CMV • Herpes simplex IgM, IgG • CSF: routine studies, quantitative VDRL, HSV PCR • Parvovirus B19 PCR • Lymphocytic choriomeningitis virus: infant IgM and IgG, mother IgG
Toxoplasmosis • Toxoplasma gondii, protozoan, cats are host • 70-90% asymptomatic • Symptoms: maculopapular rash, thrombocytopenia, lymphadenopathy, hepatomegaly, splenomegaly, jaundice, hydrocephalus, microcephaly, chorioretinitis, seizures, deafness • Diagnosis: IgM, IgG, intracranial calcifications • Treatment: pyrimethamine, sulfadiazine
Congenital Syphilis: Symptoms • Asymptomatic 50% • Fever, lymphadenopathy, irritability, failure to thrive • Jaundice, hepatosplenomegaly • Mucocutaneous: palmar/plantar bullae, maculopapular rash trunk/limbs, mucosal lesions, condylomata lata • Anemia (BM arrest, hemolysis), thrombocytopenia, low/high WBCs • Meningitis • “Snuffles” (serous rhinitis) • Bone changes: osteochondritis of humerus, tibia
Congenital Syphilis: Diagnostic Studies • Quantitative RPR • CSF exam: cell count, protein, VDRL • CBC, platelets, liver enzymes • Long bone radiographs • Demonstration of spirochetes: tissue/fluid • HIV testing
Congenital Syphilis: Treatment and Follow-up of the Newborn • Choice of regimens for confirmed or probable congenital syphilis: • Penicillin G 100-150,000 unit/kg/day x 10-14 days (50,000 unit/kg/dose IV BID x 7 days, then TID for a total of 10 days) • Procaine penicillin G 50,000 unit/kg/day IM once daily x 10 days (may not adequately treat CNS) • ampicillin is not a suitable alternative • RPR at 3, 6, 12 months • Complicated cases should be referred to specialist
Congenital Rubella: Clinical Findings • Asymptomatic: 50% at birth • Sensorineural hearing loss • Mental retardation • PDA, peripheral pulmonic stenosis • Ocular: cataracts, chorioretinitis, glaucoma • Microcephaly • Blueberry muffin rash • Metaphyseal radiolucencies
Congenital Rubella: Vertical Transmission • Transplacental passage of virus • Greatest risk for congenital defects and hearing loss early in the pregnancy • Non-immune pregnant women • do not immunize during pregnancy • no cases of malformation due to rubella vaccine in women immunized during pregnancy • avoid exposure to rubella • post-partum vaccine
Congenital Rubella: Diagnosis and Treatment • Diagnosis: • Rubella specific IgM • culture: nasopharynx, blood, urine, CSF, throat • Treatment: supportive
Cytomegalovirus: Transmission • Vertical transmission • transplacental and perinatal acquisition • maternal primary and reactivated CMV • Incidence: • 2.5% • most are asymptomatic - 95%
Cytomegalovirus: Clinical Findings In Symptomatic Infants • Microcephaly, intracranial calcifications • Thrombocytopenia, petechiae, purpura • Conjugated hyperbilirubinemia, elevated liver enzymes, liver failure • Interstitial pneumonitis • Hearing loss • Mental retardation • Neurologic impairment, cerebral palsy • Chorioretinitis • Intestinal pseudo-obstruction like illness
Cytomegalovirus: Diagnosis • CMV titers: • IgM, IgG • Acute and convalescent • Urine culture for CMV • Excretion may be intermittent • CNS imaging • Eye exam
Cytomegalovirus: Treatment • Supportive • Platelet transfusion • Anti-viral treatment • Ganciclovir may reduce sequelae, but of limited efficacy • CMV hyperimmune globulin • Infectious disease consultation
Lymphocytic choriomeningitis virus • Arenavirus, shed by rodents • Symptoms in adults: influenza like illness - fever, malaise, myalgia, retro-orbital headache, photophobia • Congenital infection: hydrocephalus, chorioretinitis, intracranial calcifications, microcephaly, mental retardation, neurologic sequelae, visual loss • Diagnosis: culture, acute and convalescent titers • Treatment: supportive
Parvovirus B19 • Associated with multiple disorders: • Erythema infectiosum (fifth disease) • Aplastic crisis (hemolytic disorders, sickle cell) • Chronic anemia in immunosuppressed • Acute arthritis • Fetal hydrops and death due to anemia • (?)Efficacy of intrauterine transfusion • Spontaneous recovery of fetal hydrops can occur
Varicella • Maternal varicella before 20 weeks: congenital anomalies reported to be 1-2% • Cicatricial skin lesions • Limb hypoplasia • CNS, ocular, neurologic • Maternal varicella in last 5 days of pregnancy to 2 days post partum: • VZIG 125 units IM indicated in exposed infants • Skin lesions, pneumonitis, dissemination reported • Add acyclovir if signs or symptoms develop
Perinatally Acquired Infection: Basic Principles • Maternal colonization or infection: • Amniotic fluid • Blood • Genital tract secretions • Breast milk • Direct skin contact, environment • Timing and duration of exposure • Interventions, prophylaxis
Herpes Simplex: Epidemiology • Vertical transmission most common • perinatal exposure with ROM and delivery • 50% risk if infant exposed to primary maternal HSV • <1-5% risk if infant exposed to recurrent maternal HSV • increased risk in premature infants (reduced IgG) • C-section reduces risk if ROM < 4-6 hour • Horizontal transmission reported • nursery outbreaks • Time of onset: 2 days - several weeks
Herpes Simplex: Clinical Presentation • Fever • skin vesicles • encephalitis • seizures • respiratory distress, pneumonia • hepatitis • septic shock like syndrome
Neonatal Herpes Simplex: Treatment • Acyclovir 60 mg/kg/day divided q 8 hr x 14 days (21 days for systemic or CNS) • Ocular HSV: add ophthalmic trifluridine, iododeoxyuridine, or vidarabine • Supportive: control seizures, respiratory and cardiovascular support • Reduce cutaneous or ocular spread • High mortality rate for CNS or systemic HSV, even with treatment
Management of HSV Exposure • Recurrent maternal HSV • risk is very low; observation only • Primary maternal disease • risk is high • viral throat culture at 24-48 hr of age • empiric therapy is controversial • Premature infant - risk may be greater
HIV • Transmission is vertical • In utero, intrapartum (most common), and postnatal (breastfeeding) • Risk factors
Zidovudine (AZT) for reduction of perinatal HIV transmission • pregnancy: begin 200 mg PO 3x/day at 14-34 wk, continue throughout pregnancy • intrapartum: 2 mg/kg x 1 h, then 1 mg/kg/h IV until delivery • newborn: 2 mg/kg 4x/day PO begining at 8-12 h of age until 6 weeks of age • referral to pediatric HIV center
HIV: perinatal prophylaxis • Reduction of vertical transmission with AZT as compared to placebo in women with mildly symptomatic disease • Connor EM et al. NEMJ 1994;331:1173 • placebo 25.5% • prenatal, intrapartum, postnatal 8.3%
HIV: Benefit persists even with abbreviated prophylaxis • DNA PCR on HIV exposed infants with incomplete prophylaxis. • Wade NA et al. NEJM 1998;339:1409 • prenatal 6.1% • intrapartum 10.0% • < 48 h postnatal 9.3% • > 48 h postnatal 18.4%
HIV: mode of delivery • Metanalysis of 15 NA/European studies • 8533 mother-child pairs • adjusted for antiretroviral Rx, maternal stage of disease and birth weight • elective C-section: prior to labor or ROM • International Perinatal HIV Group • NEJM 1999;340:977
HIV: mode of delivery • other mode (vag, non-elective C/S) 16.7% • elective C-section 8.4% • other mode, complete retroviral Rx 7.3% • elective C/S, complete retroviral Rx 2.0% • International Perinatal HIV Group • NEJM 1999;340:977